Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $51.70 Average Price Target from Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have been given a consensus rating of “Buy” by the nine ratings firms that are currently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $51.70.

MIRM has been the topic of several recent research reports. SVB Leerink lowered their price objective on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a research note on Monday, March 18th. JMP Securities upped their price target on Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, March 14th. Stifel Nicolaus initiated coverage on Mirum Pharmaceuticals in a research note on Wednesday, April 17th. They set a “buy” rating and a $48.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $35.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, February 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $58.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, April 2nd.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt bought 2,000 shares of the company’s stock in a transaction dated Wednesday, March 27th. The shares were bought at an average price of $24.80 per share, for a total transaction of $49,600.00. Following the acquisition, the chief financial officer now directly owns 14,000 shares of the company’s stock, valued at $347,200. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Eric Bjerkholt purchased 2,000 shares of the stock in a transaction dated Wednesday, March 27th. The shares were acquired at an average cost of $24.80 per share, for a total transaction of $49,600.00. Following the acquisition, the chief financial officer now directly owns 14,000 shares in the company, valued at approximately $347,200. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Peter Radovich sold 4,303 shares of the company’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $25.80, for a total transaction of $111,017.40. Following the completion of the transaction, the chief operating officer now directly owns 29,013 shares in the company, valued at $748,535.40. The disclosure for this sale can be found here. 22.87% of the stock is owned by insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Polar Capital Holdings Plc increased its position in Mirum Pharmaceuticals by 27.0% during the third quarter. Polar Capital Holdings Plc now owns 1,175,000 shares of the company’s stock worth $37,130,000 after buying an additional 250,000 shares during the last quarter. Raymond James & Associates raised its stake in shares of Mirum Pharmaceuticals by 57.1% in the 3rd quarter. Raymond James & Associates now owns 106,207 shares of the company’s stock valued at $3,356,000 after acquiring an additional 38,619 shares in the last quarter. Rafferty Asset Management LLC raised its stake in shares of Mirum Pharmaceuticals by 18.4% in the 3rd quarter. Rafferty Asset Management LLC now owns 137,205 shares of the company’s stock valued at $4,336,000 after acquiring an additional 21,312 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Mirum Pharmaceuticals by 210.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 224,571 shares of the company’s stock worth $7,096,000 after purchasing an additional 152,287 shares during the last quarter. Finally, Genworth Financial Inc acquired a new position in Mirum Pharmaceuticals during the fourth quarter valued at approximately $385,000.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ MIRM opened at $26.39 on Friday. Mirum Pharmaceuticals has a 1 year low of $23.14 and a 1 year high of $35.56. The firm has a market cap of $1.24 billion, a P/E ratio of -6.65 and a beta of 1.13. The stock has a fifty day moving average price of $26.06 and a two-hundred day moving average price of $28.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 4.19 and a current ratio of 4.45.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.32). The firm had revenue of $69.55 million during the quarter, compared to analyst estimates of $66.73 million. Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. Research analysts forecast that Mirum Pharmaceuticals will post -1.34 EPS for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.